A special Easter delivery for children at Teenage Cancer Trust unit, Nottingham
Young patients spending the Easter period in hospital got a special treat thanks to a generous donation from Quotient Clinical employees in Nottingham and Edinburgh.
Quotient Clinical incorporates Japanese bridging into a Translational Pharmaceutics® program
Quotient Clinical, the Translational Pharmaceutics company, has announced the completion of its first clinical program involving Japanese healthy volunteers.
Quotient Clinical celebrates its 100th RapidFACT® program
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT® (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues.
Quotient Clinical completes successful first US FDA Inspection
Quotient Clinical is pleased to announce that it has successfully completed its first inspection by the US Food and Drug Administration (FDA). The inspection took place on 7 – 11 December 2015 and focused on a clinical bioequivalence study conducted for a Sponsor at Quotient’s clinical facility in Nottingham, UK, with no Form 483 observations issued.
Quotient Clinical expands its formulation development services with the acquisition of Co-Formulate
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited. Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics platform, which challenges the conventional industry approach by integrating formulation development, real-time GMP manufacturing and clinical testing. The acquisition of Co-Formulate reinforces and […]